Interpace Biosciences (IDXG) Q3 2024 earnings summary

Executive summary

• Q3 2024 revenue reached $12.3 million, up 35% year-over-year, with record test volume and net income of $1.3 million, reversing a prior year loss.

• Gross margin improved to 61% in Q3 2024 from 55% in Q3 2023, reflecting higher revenue and better cost leverage.

• Operating income from continuing operations was $1.9 million in Q3 2024, up from a loss of $0.02 million in Q3 2023.

• Adjusted EBITDA for Q3 2024 was $2.1 million, up from $0.4 million in Q3 2023.

• Proprietary molecular diagnostics tests saw double-digit growth, marking the 18th consecutive quarter of year-over-year volume growth.

Financial highlights

• Q3 2024 revenue: $12.3 million (+35% year-over-year); nine-month revenue: $34.6 million (+16%).

• Q3 2024 net income: $1.3 million (vs. $0.6 million loss prior year); nine-month net income: $3.8 million (vs. $0.1 million loss prior year).

• Gross profit for Q3 2024: $7.5 million (61% margin); nine-month gross profit: $21.0 million (61% margin).

• Operating income for Q3 2024: $1.9 million; nine-month operating income: $5.0 million.

• Cash and cash equivalents at September 30, 2024: $2.1 million; $1.8 million as of November 1, 2024.

Outlook and guidance

• Current cash and forecasted receipts expected to meet requirements for the next twelve months.

• Company is seeking to uplist to Nasdaq, engaging equity research partners and investment bankers to raise capital.

• Exploring strategic alternatives, M&A activity, and additional funding sources to enhance liquidity and growth.